FRANCISCO RUGAMA: Open Payments
NPI 1780205526 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,223 in 70 payments from 21 companies in 2025. Trend: 2023 $410 · 2024 $1,292 · 2025 $1,223
Food & beverage: $1,223
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $214 |
| ABBVIE INC. | 12 | $142 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| PFIZER INC. | 5 | $101 |
| Merck Sharp & Dohme LLC | 4 | $88 |
| Lilly USA, LLC | 3 | $70 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| Verona Pharma, Inc. | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Dexcom, Inc. | 2 | $42 |
Products named: REXULTI, Ozempic, ELIQUIS, VERQUVO, TRELEGY ELLIPTA, UBRELVY, Wegovy, JARDIANCE.
Industry payments across TX — which companies pay providers there.
